Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098057 | 0.76 | GLA (0.40) | KMT2AMEN1MAPTTSHRLMNA | |
| SCHEMBL6099362 | 0.73 | MEN1 (0.43) | KMT2AMEN1USP2LMNASMN1; SMN2 | |
| SCHEMBL6095067 | 0.71 | MEN1 (0.43) | KMT2AMEN1USP2ALDH1A1NPSR1 | |
| SCHEMBL6097864 | 0.67 | MEN1 (0.40) | KMT2AMEN1MAPTUSP2LMNA | |
| SCHEMBL8857861 | 0.66 | ALDH1A1 (0.55) | KMT2AMEN1MAPTTSHRSMN1; SMN2 | |
| SCHEMBL11610302 | 0.64 | NPSR1 (0.45) | KMT2AMEN1MAPTTSHRALDH1A1 | |
| SCHEMBL5419285 | 0.64 | ALDH1A1 (0.58) | KMT2AMEN1HTTMAPTTSHR | |
| SCHEMBL8716448 | 0.64 | KMT2A (0.64) | KMT2AMEN1HTTMAPTLMNA | |
| SCHEMBL11200146 | 0.64 | MEN1 (0.44) | KMT2AMEN1MAPTTSHRLMNA | |
| SCHEMBL5416139 | 0.63 | CYP1A2 (0.68) | KMT2AMEN1HTTMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135492-B2 | Increases the concentration of high density lipoprotein cholesterol in the blood; dyslipoproteinemia; angina pectoris, myocardial infarction, antiarrhythmia agents, heart failure, kidney failure stroke, peripheral arterial occulsion | WYETH (US) | 2006-11-14 | — | — | US | claimed |
| US-20030119889-A1 | 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis | WYETH | 2003-06-26 | — | — | US | claimed |
| US-7135492-B2 | Increases the concentration of high density lipoprotein cholesterol in the blood; dyslipoproteinemia; angina pectoris, myocardial infarction, antiarrhythmia agents, heart failure, kidney failure stroke, peripheral arterial occulsion | WYETH (US) | 2006-11-14 | — | — | US | disclosed |
| US-20030119889-A1 | 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis | WYETH | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119889-A1 | 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis | FFAR4, FFAR1, MSR1 | KMT2A 3781/4885MEN1 4454/4885HTT 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.